Delayed effects of short-term transdermal application of 7-oxo-dehydroepiandrosterone on its metabolites, some hormonal steroids and relevant proteohormones in healthy male volunteers

2005 ◽  
Vol 43 (2) ◽  
Author(s):  
Jarmila Šulcová ◽  
Richard Hampl ◽  
Martin Hill ◽  
Luboslav Stárka ◽  
Alois Nováček
Keyword(s):  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Healthy Male ◽  
Delayed Effect ◽  
Short Term ◽  
Delayed Effects ◽  
Healthy Male Volunteers ◽  
Male Volunteers ◽  
Transdermal Application

AbstractTwenty-one healthy male volunteers aged 20–70years were given transdermally 25mg of 7-oxo-dehydroepiandrosterone daily in the form of an emulgel for 8 consecutive days. Morning blood was collected as follows: before application, and after the first, fourth and eighth doses (days 0, 2, 5 and 9), and then at different time intervals after termination of the treatment (days 16, 23, 37, 51, 72 and 100). Cortisol, testosterone, epitestosterone, estradiol, dehydroepiandrosterone and its sulfate, 7α- and 7β-hydroxy-dehydroepiandrosterone, luteinizing hormone, follicle-stimulating hormone and sex hormone-binding globulin were measured in blood sera. In the course of treatment 7β-hydroxy-dehydroepiandrosterone was significantly increased; testosterone and gonadotropins were lowered, but only after the first dose. All other significant changes were observed duringthe period after termination of the application:7β-hydroxy-dehydroepiandrosterone remained increased for 28days, 7α-hydroxy-dehydroepiandrosterone, testosterone, estradiol and sex hormone-binding globulin were decreased as late as day 63 and 91, respectively. On the other hand, epitestosterone was significantly increased between days 23 and 100. The levels of all other parameters studied were not significantly changed. The study points to an immediate as well as delayed effect of the short-term transdermal application of 7-oxo-dehydroepiandrosterone on relevant hormonal parameters.

Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers

1997 ◽  
Vol 43 (1) ◽  
pp. 104-108 ◽  
Author(s):  
José Pedrazzoli Júnior ◽  
Marcos de Almeida Pierorsi ◽  
Marcelo Nicolás Muscará ◽  
Heidi Bernadetta Dias ◽  
Claudia Maria Ferreira da Silva ◽  
...  
Keyword(s):  
Healthy Male ◽  
Short Term ◽  
Healthy Male Volunteers ◽  
Male Volunteers

Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency

2015 ◽  
Vol 11 (3) ◽  
pp. 211 ◽  
Author(s):  
Gary Eichenbaum, PhD ◽  
Karin Göhler, MD ◽  
Mila Etropolski, MD ◽  
Ilona Steigerwald, MD, PhD ◽  
Joseph Pergolizzi, MD ◽  
...  
Keyword(s):  
Single Dose ◽  
Medical Research ◽  
Healthy Volunteers ◽  
Opioid Analgesics ◽  
Sex Hormone ◽  
Androgen Deficiency ◽  
Research Centers ◽  
Healthy Male ◽  
Healthy Male Volunteers ◽  
Male Volunteers

Objectives: Opioid-induced androgen deficiency (OPIAD) affects patients treated with opioid analgesics. The norepinephrine reuptake inhibitor (NRI) and μ-opioid receptor (MOR) agonist activities of tapentadol may result in tapentadol having less effect on serum androgen concentrations than analgesics acting through the MOR alone, such as morphine and oxycodone. The objectives of this publication are to 1) evaluate the effects of tapentadol (NUCYNTA and NUCYNTA extended release [ER]) on sex hormone concentrations in healthy male volunteers (vs placebo and morphine) and patients with osteoarthritis (vs placebo and oxycodone), and 2) present a mechanistic hypothesis explaining how the combined MOR agonist and NRI activities of tapentadol may result in less impact on androgen concentrations. Methods: Three clinical studies were conducted: study 1 (single-dose comparison study vs morphine in healthy volunteers), study 2 (single-dose-escalation study in healthy volunteers without an active comparator), and study 3 (multiple-dose study vs oxycodone in patients with osteoarthritis). Studies 1 and 2 were conducted at medical research centers in Germany and the United Kingdom; study 3 was conducted at primary and secondary care centers and medical research centers in the United States. All three studies were randomized, double blind, and placebo controlled. Concentrations of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH; study 3 only) were evaluated at 6 and 24 hours postdose in studies 1 and 2, respectively, and at varying time points postdose in study 3.Results: In study 1, mean serum total testosterone concentrations in healthy male volunteers were similar at baseline for all treatment periods; 6 hours after dosing, mean concentrations were comparable between placebo (8.6 nmol/L) and tapentadol immediate release (IR; 43 mg, 8.8 nmol/L; 86 mg, 9.3 nmol/L), but were lower following administration of morphine IR 30 mg (5.4 nmol/L). In study 2, there were no or minimal changes in testosterone in the therapeutic dose range with tapentadol IR (75-100 mg), and there was a modest decrease that appeared to level off in the supratherapeutic range (125-175 mg); mean testosterone and LH concentrations with all doses remained within normal ranges (testosterone, 4.56-28.2 nmol/L; LH, 2.9-4.6 U/L). In study 3, the decrease in the mean [standard deviation] testosterone concentration from baseline to endpoint for male patients receiving tapentadol ER (100 mg, −1.9 [0.71] nmol/L; 200 mg, −2.1 [0.93] nmol/L) was numerically smaller compared to oxycodone CR (20 mg, −2.7 [0.93] nmol/L), but higher compared to placebo (−0.3 [1.62] nmol/L).Conclusions: These results suggest that tapentadol, which has combined MOR and NRI activities, may have a lower impact on sex hormone concentrations than pure opioid analgesics, such as morphine or oxycodone. The data and mechanistic rationale presented herein provide a justification for conducting additional hypothesis testing studies, and are not intended to be used as a basis for clinical decision making. Future studies may help elucidate whether the observed trends are clinically significant and would translate into a reduced incidence of OPIAD.

scholarly journals Sex difference determined the role of sex hormone-binding globulin in obese children during short-term weight reduction program

Medicine ◽  
2017 ◽  
Vol 96 (19) ◽  
pp. e6834 ◽  
Author(s):  
Fu-Min Wang ◽  
Chien-Ming Lin ◽  
Shao-Hung Lien ◽  
Li-Wei Wu ◽  
Ching-Feng Huang ◽  
...  
Keyword(s):  
Sex Difference ◽  
Weight Reduction ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Obese Children ◽  
Short Term ◽  
Weight Reduction Program ◽  
Reduction Program

scholarly journals Short Term Cardiovascular Effects of Aldosterone in Healthy Male Volunteers*

1999 ◽  
Vol 84 (10) ◽  
pp. 3528-3533 ◽  
Author(s):  
B. M. W. Schmidt ◽  
A. Montealegre ◽  
C. P. Janson ◽  
N. Martin ◽  
C. Stein-Kemmesies ◽  
...  
Keyword(s):  
Cardiovascular Effects ◽  
Healthy Male ◽  
Short Term ◽  
Healthy Male Volunteers ◽  
Male Volunteers

scholarly journals Short-term sucralfate administration alters potassium diclofenac absorption in healthy male volunteers

1997 ◽  
Vol 43 (1) ◽  
pp. 104-108
Author(s):  
José Pedrazzoli Júnior ◽  
Marcos de Almeida Pierorsi ◽  
Marcelo Nicolás Muscará ◽  
Heidi Bernadetta Dias ◽  
Claudia Maria Ferreira da Silva ◽  
...  
Keyword(s):  
Healthy Male ◽  
Short Term ◽  
Healthy Male Volunteers ◽  
Male Volunteers

Effects of oestradiol on sex hormone binding globulin

1982 ◽  
Vol 101 (2) ◽  
pp. 248-253 ◽  
Author(s):  
Viveca Odlind ◽  
Kerstin Elamsson ◽  
Doris E. Englund ◽  
Arne Victor ◽  
Elof D. B. Johansson
Keyword(s):  
Luteal Phase ◽  
Sex Hormone ◽  
Sex Hormone Binding Globulin ◽  
Hormone Binding ◽  
Pronounced Increase ◽  
Menstrual Cycles ◽  
Menopausal Women ◽  
Plasma Oestradiol

Abstract. Sex hormone binding globulin (SHBG) levels were studied for possible effects of oestradiol-17β on SHBG. No change in SHBG plasma was recorded during normal menstrual cycles or during treatment with oestradiol-17β to menopausal women. However, gonadotrophin treatment to amenorrhoeic women to induce ovulation resulted in high oestradiol concentrations and a pronounced increase in SHBG was found during the luteal phase of these cycles. A marked increase of SHBG was also recorded in a woman with pronounced fluctuations of oestradiol during treatment with levonorgestrel sc implants for contraception. In conclusion, effects on SHBG were only found when extraordinarily high levels of plasma oestradiol were recorded.

Sign in / Sign up

Export Citation Format

Share Document